Biologics represent about 40 percent of drugs in the therapeutics development pipeline, and currently account for more than $200 billion in annual global revenue. It is an area primed for extraordinary growth. But research and development by pharmaceutical companies and manufacturers— and academic research centers—are limited by the lack of trained professionals in this field.
To meet these critical workforce needs, Jefferson established Jefferson Institute for Bioprocessing (JIB). It is the first—and only—specialized education and training institute for biopharmaceutical processing in North America that combines commercial single-use processing equipment with a curriculum created in collaboration with the Ireland-based National Institute for Bioprocessing Research and Training (a joint effort of University College Dublin, Trinity College Dublin, Dublin City University and the Institute of Technology, Sligo). JIB—which opened its 25,000 square foot training and education facility in May 2019—provides training to industry professionals through workshops and certificate programs and hands-on education of new bioprocessing engineers at the undergraduate and graduate levels. “This is the kind of facility you see in a manufacturing setting,” says Parviz Shamlou, PhD, JIB’s executive director. “It is, we believe, unique among academic institutions.”
"Jefferson Institute for Bioprocessing: Advancing Biologies R&D,"
Thomas Jefferson University Research Magazine: Vol. 1:
1, Article 10.
Available at: https://jdc.jefferson.edu/researchmagazine/vol1/iss1/10